Download PDF

1. Company Snapshot

1.a. Company Description

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics.The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders.


In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system.Intellia Therapeutics, Inc.has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc.


to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc.to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases.The company was formerly known as AZRN, Inc.


Intellia Therapeutics, Inc.was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Show Full description

1.b. Last Insights on NTLA

Intellia Therapeutics' recent momentum is driven by strong progress in its late-stage gene editing therapies. The company's lead candidate, lonvo-z, has completed Phase 3 enrollment for hereditary angioedema (HAE), offering a one-time infusion advantage over competitors. Recent earnings report showed a narrower Q2 loss and beat on revenues. Additionally, Cathie Wood's Ark Invest has taken a position in the stock, and Intellia's gene therapy pipeline progress has garnered growing investor attention. (Source: Zacks, Globe Newswire)

1.c. Company Highlights

2. Intellia Therapeutics: Clinical Hold Clouds Otherwise Promising Pipeline

Intellia Therapeutics reported a net loss per share of -$0.92 in Q3 2025, beating estimates of -$1.02. The company's cash, cash equivalents, and marketable securities stood at $669.9 million as of September 30, 2025, extending its cash runway into mid-2027. Revenue growth is expected to be negative at -11.4% next year, indicating a challenging period ahead.

Publication Date: Nov -23

📋 Highlights
  • Clinical Hold on Nex-z Trials:: FDA placed a clinical hold on MAGNITUDE and MAGNITUDE-2 trials after a patient experienced liver function abnormalities, halting dosing and screening.
  • Enrollment Progress:: Over 650 patients enrolled in MAGNITUDE and 47 in MAGNITUDE-2, with <1% reporting Grade 4 liver transaminase elevations.
  • Financial Position:: $669.9M cash reserves as of Q3 2025, extending runway through mid-2027 and supporting lonvo-z’s anticipated 2027 U.S. launch.
  • Lonvo-z HAELO Trial:: Enrollment completed in September 2025, with top-line data expected by mid-2026 and FDA BLA submission planned for late 2026.
  • Capital Strategy:: Company is evaluating ATM offerings, collaborations, and debt to maintain financial flexibility amid regulatory review of nex-z’s liver safety data.

Financial Performance

The company's financial performance was marked by a significant net loss, but the actual EPS loss was narrower than expected. With a solid balance sheet, Intellia is well-positioned to navigate the challenges ahead, including the clinical hold on its nex-z program. As Edward Dulac noted, "Intellia continues to maintain a solid balance sheet, with $669.9 million in cash, cash equivalents, and marketable securities as of September 30, 2025."

Clinical Hold on nex-z Program

A clinical hold was placed on the MAGNITUDE and MAGNITUDE-2 trials due to a patient experiencing liver function test abnormalities after receiving a dose of nex-z. The company is working closely with regulatory authorities to understand the requirements to lift the hold. With over 650 patients enrolled in MAGNITUDE and 47 in MAGNITUDE-2, the incidence of Grade 4 liver transaminase elevations was less than 1%.

Valuation Metrics

Intellia's valuation metrics indicate a challenging environment. The stock trades at a P/S Ratio of 14.95, EV/EBITDA of -2.13, and a P/E Ratio of -2.03, suggesting that the market is pricing in significant growth challenges. The company's ROE and ROIC are also negative, at -57.24% and -42.76%, respectively.

lonvo-z Program

Despite the setback with nex-z, Intellia's lonvo-z program continues to progress. The HAELO Phase III clinical trial has completed enrollment, and top-line data is expected by mid-2026. The company is on track to submit a BLA to the FDA in the second half of 2026 and prepare for a commercial launch in the U.S. in the first half of 2027.

Future Prospects

The clinical hold on nex-z is a significant near-term challenge, but Intellia's lonvo-z program and solid balance sheet provide a foundation for future growth. As John Leonard stated, "We're working on understanding the clinical course of the patient and will present the information at the appropriate time." The company's ability to navigate the clinical hold and advance its pipeline will be crucial in determining its future prospects.

3. NewsRoom

Card image cap

Geode Capital Management LLC Boosts Holdings in Intellia Therapeutics, Inc. $NTLA

Nov -29

Source: defenseworld.net

Card image cap

Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry?

Nov -28

Source: zacks.com

Card image cap

BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential?

Nov -27

Source: zacks.com

Card image cap

AXQ Capital LP Buys New Position in Intellia Therapeutics, Inc. $NTLA

Nov -25

Source: defenseworld.net

Card image cap

NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock?

Nov -21

Source: zacks.com

Card image cap

2 Beaten-Down Stocks to Avoid Right Now

Nov -15

Source: fool.com

Card image cap

2 Beaten-Down Stocks to Avoid Right Now

Nov -15

Source: fool.com

Card image cap

Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks?

Nov -14

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (14.60%)

6. Segments

Genome Editing-based Therapies

Expected Growth: 14.6%

Intellia Therapeutics' 14.6% growth in Genome Editing-based Therapies is driven by increasing adoption of CRISPR technology, strong pipeline of novel treatments for genetic diseases, strategic partnerships, and growing demand for precision medicine. Additionally, advancements in gene editing tools, expanding research collaborations, and favorable regulatory environments contribute to the segment's rapid expansion.

7. Detailed Products

CRISPR/Cas9 Gene Editing

A precise and efficient gene editing technology for treating genetic diseases

CRISPR/Cas12a Gene Editing

A novel gene editing technology for treating genetic diseases with high precision and efficiency

In Vivo CRISPR Gene Editing

A gene editing technology for treating genetic diseases directly in the body

Ex Vivo CRISPR Gene Editing

A gene editing technology for treating genetic diseases outside of the body

Gene Regulation Therapies

A technology for regulating gene expression to treat genetic diseases

8. Intellia Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Intellia Therapeutics, Inc. is medium due to the presence of alternative gene editing technologies such as CRISPR-Cas9 and TALEN. However, Intellia's proprietary CRISPR-Cas12a technology provides a unique advantage in terms of precision and efficiency.

Bargaining Power Of Customers

The bargaining power of customers for Intellia Therapeutics, Inc. is low due to the company's focus on developing novel gene editing therapies for rare genetic diseases, which provides a high level of differentiation and limited alternatives for customers.

Bargaining Power Of Suppliers

The bargaining power of suppliers for Intellia Therapeutics, Inc. is medium due to the company's reliance on a few key suppliers for raw materials and equipment. However, the company's strong relationships with suppliers and its ability to negotiate favorable terms mitigate this risk.

Threat Of New Entrants

The threat of new entrants for Intellia Therapeutics, Inc. is high due to the growing interest in gene editing technologies and the potential for new companies to enter the market. However, Intellia's strong intellectual property position and expertise in CRISPR-Cas12a technology provide a barrier to entry for new competitors.

Intensity Of Rivalry

The intensity of rivalry for Intellia Therapeutics, Inc. is high due to the competitive landscape of the gene editing industry, with multiple companies vying for market share and intellectual property dominance. However, Intellia's focus on rare genetic diseases and its proprietary technology provide a unique competitive advantage.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 9.90%
Debt Cost 3.95%
Equity Weight 90.10%
Equity Cost 13.15%
WACC 12.24%
Leverage 10.98%

11. Quality Control: Intellia Therapeutics, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
ACADIA Pharmaceuticals

A-Score: 5.6/10

Value: 3.0

Growth: 9.0

Quality: 9.1

Yield: 0.0

Momentum: 9.0

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
TG Therapeutics

A-Score: 4.8/10

Value: 2.0

Growth: 8.2

Quality: 7.7

Yield: 0.0

Momentum: 8.5

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
Axsome Therapeutics

A-Score: 4.6/10

Value: 6.0

Growth: 4.1

Quality: 3.6

Yield: 0.0

Momentum: 9.0

Volatility: 5.0

1-Year Total Return ->

View Full Report
Stock-Card
Arrowhead Pharmaceuticals

A-Score: 3.9/10

Value: 6.2

Growth: 1.1

Quality: 4.2

Yield: 0.0

Momentum: 10.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Intellia Therapeutics

A-Score: 3.4/10

Value: 7.0

Growth: 2.8

Quality: 4.8

Yield: 0.0

Momentum: 4.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Ultragenyx Pharmaceutical

A-Score: 3.0/10

Value: 6.4

Growth: 4.7

Quality: 3.5

Yield: 0.0

Momentum: 0.0

Volatility: 3.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

9.61$

Current Price

9.61$

Potential

-0.00%

Expected Cash-Flows